-- Scott Roberts
FRIDAY, March 21, 2014 (HealthDay News) -- Otezla (apremilast)
has been approved by the U.S. Food and Drug Administration to treat
adults with active psoriatic arthritis, a condition associated with
the autoimmune skin disease psoriasis.
Most people develop psoriasis first and are subsequently
diagnosed with psoriatic arthritis. Common symptoms of the latter
are joint pain, stiffness and swelling.
Otezla was evaluated in clinical studies involving nearly 1,500
people with active psoriatic arthritis. In a Friday news release,
the FDA said Otezla users should be monitored carefully for
unexplained weight loss or signs of depression. Pregnant women must
register for the drug's use, the agency added.
The most common side effects noted during clinical testing
included diarrhea, nausea and headache.
Otezla is produced for Celgene Corp., based in Summit, N.J.
The FDA has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.